BridgeBio Pharma

A big week at #ICCBH2026 for BridgeBio with one late-breaking oral, one additional oral, and four posters spanning achondroplasia, hypochondroplasia, and ADH1. The standout moment: Dr. Ravi Savarirayan announced live that our Phase 3 PROPEL 3 data is now published in @NEJM. Thank you to the investigators, advocates, and, most of all, the children and families whose participation makes this research possible.

It’s muscular dystrophy, but is it limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9)? Learn more about genetic confirmation of limb-girdle muscular dystrophy (LGMD) subtypes and testing support at KnowLGMD.com

For Arielle (and later, her son Sebastian), years of seizures, specialists, and uncertainty would finally lead to genetic testing providing an answer: a diagnosis of autosomal dominant hypocalcemia type 1 (#ADH1). Arielle's strong advocacy for her son in the face of many challenges is all-too-common when navigating rare disease. Thank you to @CNBC Cures for featuring Arielle's #ADH1 story in the latest installment of its ongoing #raredisease coverage. Read more here: cnb.cx/4vYHPOb

More than half of #ATTRCM patients also have atrial fibrillation, a combination that complicates diagnosis, management, and prognosis. New research in @JCardiacFailure led by @BrettSperryMD examines what that could mean for patient care. 🔗 bit.ly/4uN8g7R

Genetic testing is essential. So is knowing when to test. Visit KnowLGMD.com to learn about accurate, rapid, and minimally invasive diagnostic tests for limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

Proud to share: Adora Ndu, our Chief Regulatory Officer & EVP of Portfolio Strategy and Management, has been named a Luminary in the BLOC 100, recognizing 100 women of color and allies shaping the future of biopharma and life sciences. Nominated by peers. Earned entirely. Congratulations. 🙌

We're at #ICNMD2026 in Florence this week. Catch up with us at Booth 240 or learn more about our interim analysis of our ongoing Phase 3 FORTIFY study of BBP-418 in individuals with LGMD2I/R9.

New in @American_Heart @CircAHA: Heart Failure – Post-hoc analyses from the ATTRibute-CM trial describe changes in kidney function parameters observed with acoramidis treatment, including an early and sustained reduction in UACR, a marker of kidney damage, and a reduction in the rate of decline in kidney function as measured by eGFR slope.  bit.ly/3SsHvs6 #ATTRCM #CardioTwitter

We raised up to $1B in preferred equity from Sixth Street and HealthCare Royalty to accelerate Attruby global expansion, support three near-term U.S. product launches, and invest in expansion indications in our pipeline. bit.ly/4eTii1i $BBIO

Phase 3 PROPEL 3 data published today in @NEJM and shared at the @childrensbones ICCBH 2026. For children living with achondroplasia, this is a landmark moment & and it belongs to every family who made it possible. Learn more about the data: bit.ly/3R7PM4d

10,000+ rare diseases. ~500 with approved therapies. Most with the genetic cause already known. The science is ready. What's required now is the structure to pursue it intelligently. Different diseases. Different mechanisms. Different shots on goal. 🎥 bit.ly/3RPZ9FD

With limb-girdle muscular dystrophy (LGMD), a patient’s symptoms, family history, and creatine kinase levels may raise flags. Confirming a specific variant through genetic testing offers an accurate, rapid, and minimally invasive approach to diagnose an LGMD subtype. Get to know LGMD2I/R9 at KnowLGMD.com/genetic-testing

We are presenting at @childrensbones #ICCBH2026 in Montreal, including primary results from our Phase 3 PROPEL 3 trial of oral infigratinib for children with achondroplasia. Full agenda: bit.ly/4uIKdXI

This Father's Day, here's to the dads who help us through the hard days, celebrate the wins, and remind us that anything is possible. To every father whose life has been touched by a genetic condition, we celebrate all that you are and all that you do. Happy Father’s Day.

The rare disease community doesn't need a better conversation. It needs action. At @eurodis’s #ECRD2026, we joined advocates, regulators, and people living with rare conditions to push for faster diagnosis, equitable access, and reimbursement pathways that work. We also connected with Florian Innig of @bkmf to align on advancing advocacy for people living with achondroplasia across Europe. Every minute counts. 🤝

Slow failure is the real enemy in drug development. Every extra minute on the wrong path is time patients don't get back. We design programs to reach real answers faster and to stop quickly when a medicine isn't working. That's not giving up. That's the job. 🎥 bit.ly/3RPZ9FD

Arielle, thank you for trusting us with your story. Because of people like you, awareness grows. Diagnoses happen sooner. Families get answers. 🎧 Listen to the full episode of Arielle’s journey: bit.ly/4tUabaO

The latest insights on limb-girdle muscular dystrophy 2I/R9 (LGMD2I/R9) are easily found. Visit KnowLGMD.com and explore the LGMD2I/R9 landscape.

🚐 Something is rolling into @theENDOsociety #ENDO2026 and it's never been done before. We're unveiling a first-of-its-kind mobile genetic testing van. On-site genetic testing through @PrevGenetics for ADH1 and hypoparathyroidism. One cheek swab. Zero cost. Come find us. Then watch us take it on the road. 🧬 Learn more: bit.ly/4aLT03T

Primary results from the CALIBRATE trial evaluating encaleret in ADH1 will be presented at @theENDOsociety’s #ENDO2026 on Saturday, June 13th at 2 PM CDT. Plus two posters on the genetics and patient experience of ADH1 on Monday, June 15.